Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease

Journal of Clinical Oncology

Volumn 34, Issue 10, 2016, Pages 1112-1121

  Brudno, Jennifer N ^a   Somerville, Robert P T ^a   Shi, Victoria ^a   Rose, Jeremy J ^a   Halverson, David C ^a   Fowler, Daniel H ^a   Gea Banacloche, Juan C ^a   Pavletic, Steven Z ^a   Hickstein, Dennis D ^a   Lu, Tangying L ^a   Feldman, Steven A ^a   Iwamoto, Alexander T ^a   Kurlander, Roger ^b   Maric, Irina ^b   Goy, Andre ^d   Hansen, Brenna G ^a   Wilder, Jennifer S ^a,c   Blacklock Schuver, Bazetta ^a   Hakim, Frances T ^a   Rosenberg, Steven A ^a   Gress, Ronald E ^a   Kochenderfer, James N ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DONOR LYMPHOCYTE INFUSION; DYSPNEA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; LARGE CELL LYMPHOMA; LEUKEMIA REMISSION; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; TACHYCARDIA; ADVERSE EFFECTS; ALLOTRANSPLANTATION; DISEASE COURSE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGY; LEUKEMIA, B-CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; REMISSION; T LYMPHOCYTE; TRANSPLANTATION;

ADULT; AGED; ANTIGENS, CD19; DISEASE PROGRESSION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, B-CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; REMISSION INDUCTION; T-LYMPHOCYTES; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS;

EID: 84963594644     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.5929     Document Type: Article

References (42)

1. Khouri IF, Champlin RE: Nonmyeloablative allogeneic stem cell transplantation for non-Hodgkin lymphoma. Cancer J 18:457-462, 2012
2. Pavletic SZ, Kumar S, Mohty M, et al; NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse Following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant 16:871-890, 2010
3. van den Brink MR, Porter DL, Giralt S, et al: Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant 16:S138-S145, 2010
4. Spyridonidis A, Labopin M, Schmid C, et al: Immunotherapy Subcommittee of Acute Leukemia Working Party: Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia 26:1211-1217, 2012
5. Thomson KJ, Morris EC, Bloor A, et al: Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 27:426-432, 2009
6. Roddie C, Peggs KS: Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 11:473-487, 2011
7. Kolb H-J: Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112:4371-4383, 2008
8. Kolb HJ, Schattenberg A, Goldman JM, et al: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia: Graftversusleukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-2050, 1995
9. Frey NV, Porter DL: Graft-versus-host disease after donor leukocyte infusions: Presentation and management. Best Pract Res Clin Haematol 21:205-222, 2008
10. Marcus A, Eshhar Z: Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Expert Opin Biol Ther 14:947-954, 2014
11. Ghorashian S, Pule M, Amrolia P: CD19 chimeric antigen receptor T cell therapy for haematological malignancies. Br J Haematol 169:463-478, 2015
12. Kochenderfer JN, Rosenberg SA: Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 10:267-276, 2013
13. Eshhar Z, Waks T, Gross G, et al: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 90:720-724, 1993
14. Kochenderfer JN, Feldman SA, Zhao Y, et al: Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 32:689-702, 2009
15. Brentjens RJ, Latouche JB, Santos E, et al: Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9:279-286, 2003
16. [Comment: Nat Med 9:257-258, 2003]
17. Cooper LJ, Topp MS, Serrano LM, et al: T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-Blineage leukemia effect. Blood 101:1637-1644, 2003
18. Kochenderfer JN, Wilson WH, Janik JE, et al: Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116:4099-4102, 2010
19. Porter DL, Levine BL, Kalos M, et al: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733, 2011
20. Brentjens RJ, Davila ML, Riviere I, et al: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra38, 2013
21. Kochenderfer JN, Dudley ME, Kassim SH, et al: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33:540-549, 2015
22. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 385:517-528, 2015
23. Kochenderfer JN, Dudley ME, Feldman SA, et al: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigenreceptortransduced T cells. Blood 119:2709-2720, 2012
24. Davila ML, Riviere I, Wang X, et al: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra25, 2014
25. Kochenderfer JN, Dudley ME, Carpenter RO, et al: Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122:4129-4139, 2013
26. Cruz CRY, Micklethwaite KP, Savoldo B, et al: Infusion of donor-derived CD19-redirected virusspecific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study. Blood 122:2965-2973, 2013
27. Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825-828, 1995
28. Filipovich AH, Weisdorf D, Pavletic S, et al: National Institutes of Health consensus development project on criteria for clinical trials in chronic graftversushost disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945-956, 2005
29. Jena B, Maiti S, Huls H, et al: Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One 8:e57838, 2013
30. Cheson BD, Pfistner B, Juweid ME, et al: International Harmonization Project on Lymphoma: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
31. Hallek M, Cheson BD, Catovsky D, et al: International Workshop on Chronic Lymphocytic Leukemia: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008
32. Lee DW, Gardner R, Porter DL, et al: Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188-195, 2014
33. [Erratum: Blood 126:1048, 2015]
34. Sallusto F, Lenig D, Förster R, et al: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-712, 1999
35. Wherry EJ: T cell exhaustion. Nat Immunol 12:492-499, 2011
36. Vincent K, Roy DC, Perreault C: Nextgeneration leukemia immunotherapy. Blood 118:2951-2959, 2011
37. Warren EH, Deeg HJ: Dissecting graftversusleukemia from graft-versus-host-disease using novel strategies. Tissue Antigens 81:183-193, 2013
38. Mackinnon S, Papadopoulos EB, Carabasi MH, et al: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261-1268, 1995
39. Gattinoni L, Finkelstein SE, Klebanoff CA, et al: Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202:907-912, 2005
40. Kochenderfer JN, Yu Z, Frasheri D, et al: Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116:3875-3886, 2010
41. Maude SL, Frey N, Shaw PA, et al: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507-1517, 2014
42. Tumeh PC, Harview CL, Yearley JH, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568-571, 2014